시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 중증근무력증 치료 시장 보고서(2025년)
Myasthenia Gravis Treatment Global Market Report 2025
상품코드 : 1824416
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

중증근무력증 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.9%로 성장할 전망이며, 22억 5,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 생물학적 제제 및 단일클론항체, 유전자 의료 및 정밀 의료, 신흥 면역조절제, 신경보호 전략, 바이오시밀러 의약품에 기인할 것으로 보입니다. 예측 기간 주요 동향에는 디지털 치료제, 공동 연구 이니셔티브, 환자 중심 접근법, 실제 세계 증거 활용, 장기 안전 모니터링 등이 포함됩니다.

향후 5년간의 성장률 7.9%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 장벽은 오스트리아와 아일랜드에서 조달하는 정맥내 면역글로불린(IVIG)과 아세틸콜린 에스테라아제 억제제의 비용을 상승시킴으로써 미국을 억제하고, 자가면역 증상의 재연을 악화시키며, 신경내과의 치료비를 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

중증근무력증의 이환율 증가는 향후 중증근무력증 치료 시장의 성장을 이끌 것으로 예측됩니다. 중증근무력증은 골격근의 피로와 근력 저하를 특징으로 하는 자가면역 신경근 질환입니다. 중증근무력증의 치료에는 환자가 상태를 관리할 수 있도록 헬스케어 서비스 및 치료를 제공하는 것이 포함됩니다. 그 결과, 중증근무력증의 유병률 증가가 치료 시장의 매출을 늘리고 있습니다. 예를 들어, 전미 희귀질환 기구가 2022년 1월에 발표한 데이터에 의하면, 중증근무력증의 자가면역성 유병률은 미국에서 10만 명당 14-40명으로 추정되고 있습니다. 게다가 2024년 4월에 미국 Journal of Managed Care 잡지가 발표한 보고에서는 연간 평균 1,800례의 진단에 근거해, 10만 명당 발병률은 4.32례, 10만 명당 년간 발병률은 2.46례로 추정되고 있습니다. 이와 같이 중증근무력증의 유병률 증가가 중증근무력증 치료 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of intravenous immunoglobulin (IVIG) and acetylcholinesterase inhibitors sourced from Austria and Ireland, thereby exacerbating autoimmune symptom flare-ups and elevating neurology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rise in the incidence of myasthenia gravis is anticipated to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness in the skeletal muscles. Treatment for myasthenia gravis involves delivering healthcare services and care to help patients manage the condition. Consequently, the increasing prevalence of myasthenia gravis is enhancing sales in the treatment market. For instance, data published by the National Organization for Rare Disorders in January 2022 indicated that autoimmune myasthenia gravis has an estimated prevalence of 14-40 per 100,000 individuals in the United States. Additionally, a report from the American Journal of Managed Care in April 2024, based on an average of 1,800 annual diagnoses, estimated an incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Thus, the growing prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

Rising healthcare spending is fueling growth in the myasthenia gravis treatment market. Healthcare spending represents the total financial resources allocated to the healthcare sector within a given region, country, or organization. Such spending is essential for treating myasthenia gravis (MG), an autoimmune neuromuscular disorder, as it supports optimal patient care, symptom management, and enhanced quality of life. For example, in July 2024, the American Medical Association, a U.S.-based professional association and lobbying group of physicians and medical students, reported that health spending in the United States rose by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per capita. Therefore, increased healthcare spending is propelling the growth of the myasthenia gravis treatment market.

Product innovations are becoming a significant trend in the myasthenia gravis treatment market. Key companies in this sector are concentrating on developing new solutions to maintain their competitive edge. For example, in October 2023, UCB Pharma, a pharmaceutical company based in Belgium, announced that the US Food and Drug Administration (FDA) approved Zilucoplan for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval adds a new treatment option for managing gMG, which is characterized by muscle weakness stemming from an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient alternative to the traditional intravenous therapies that have long been the standard for treating gMG.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In November 2023, Selecta Biosciences, Inc., a biotechnology company based in the United States, announced its merger with Cartesian Therapeutics for an undisclosed amount. This merger enhances Selecta's dedication to RNA cell therapies for autoimmune diseases, particularly myasthenia gravis (MG). The partnership aims to leverage Cartesian's advanced RNA-engineering platform and pipeline, which includes the promising rCAR-T therapy Descartes-08, to accelerate development and provide effective treatment options. Cartesian Therapeutics is also a US-based biotechnology company focused on developing potential treatments for generalized myasthenia gravis.

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myasthenia Gravis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myasthenia gravis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for myasthenia gravis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The myasthenia gravis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Myasthenia Gravis Treatment Growth Analysis And Strategic Analysis Framework

6. Myasthenia Gravis Treatment Market Segmentation

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

8. Asia-Pacific Myasthenia Gravis Treatment Market

9. China Myasthenia Gravis Treatment Market

10. India Myasthenia Gravis Treatment Market

11. Japan Myasthenia Gravis Treatment Market

12. Australia Myasthenia Gravis Treatment Market

13. Indonesia Myasthenia Gravis Treatment Market

14. South Korea Myasthenia Gravis Treatment Market

15. Western Europe Myasthenia Gravis Treatment Market

16. UK Myasthenia Gravis Treatment Market

17. Germany Myasthenia Gravis Treatment Market

18. France Myasthenia Gravis Treatment Market

19. Italy Myasthenia Gravis Treatment Market

20. Spain Myasthenia Gravis Treatment Market

21. Eastern Europe Myasthenia Gravis Treatment Market

22. Russia Myasthenia Gravis Treatment Market

23. North America Myasthenia Gravis Treatment Market

24. USA Myasthenia Gravis Treatment Market

25. Canada Myasthenia Gravis Treatment Market

26. South America Myasthenia Gravis Treatment Market

27. Brazil Myasthenia Gravis Treatment Market

28. Middle East Myasthenia Gravis Treatment Market

29. Africa Myasthenia Gravis Treatment Market

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

34. Recent Developments In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기